Fangda Holdings (01521) announced the results for the year ended December 31, 2023. The group obtained 2 profits...
According to the Zhitong Finance App, Fangda Holdings (01521) announced results for the year ended December 31, 2023. The group obtained revenue of US$260 million, an increase of 3.8% year on year; profit attributable to company owners was US$10.808 million, a decrease of 58% year on year; adjusted net profit of US$24 million, a decrease of 33.7% year on year; and basic profit per share.
Looking forward to the future, the company is committed to enhancing its position as a value-added partner in the biopharmaceutical industry, focusing on providing high-quality services to customers in the biopharmaceutical sector to help them solve the most critical and complex drug development challenges. The company plans to continue to optimize the company's comprehensive service platform and develop cutting-edge technology platforms to ensure that the company can meet the diverse needs of customers from drug discovery to development. The company will consider making reasonable investments in areas where demand is strong and growth opportunities are high, such as pathology, genotoxicity, and other areas of expertise.